biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Chiesi next week

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon Jan 18, 2023 1:22pm

80 Views

Post# 35231016

RE:RE:RE:RE:Chiesi next week

Bioasis did "Hunter" work with Scarpa starting back in September 2014.

The work was a success but, if I recall correctly, there were problems with the storage of the control tissues. That prevented a paper from being written. I think that more work was also needed on heparan sulphate data. I believe that the data deficiency was being worked on for a potential deal but the potential partner, that I won't name, had other problems not related to Bioasis and sort of self-destructed for a while.

Yes, some preclincal work appears to have been done. I don't recall anything subsequent to that.

jd

<< Previous

Bullboard Posts

Next >>

Three micro-cap stocks on an upswing worth riding